Spark Therapeutics

Roche culls ph. 3 Spark gene therapy in hemophilia

After the elimination of a gene therapy study last week, Roche confirmed that it’s axing a hemophilia candidate from its buyout of Spark Therapeutics.

Fraiser Kansteiner Dec 16, 2024 12:24pm

Roche bets up to $1B to expand Dyno gene therapy delivery pact

Oct 24, 2024 10:40am

Fierce 15: Where are they now?

Jul 26, 2024 6:50am

Roche pumps brakes in Pompe after assessing competition

Jul 25, 2024 6:32am

SpliceBio sparks eye disease gene therapy collab with Roche unit

Oct 17, 2023 3:00am

Atsena downsizes to funnel money toward new capsid program

Oct 5, 2023 1:47pm